卵巢癌血清标志物的临床应用  

Clinical application of serum biomarkers for ovarian cancer

作　　者：宋斌斌[1] 潘柏申[1] 

机构地区：[1]复旦大学附属中山医院检验科,上海200032

出　　处：《检验医学》2015年第8期866-870,共5页Laboratory Medicine

基　　金：国家临床重点检验专科建设项目

摘　　要：卵巢癌死亡率在女性所有肿瘤死亡率中居第5位,妇科肿瘤中居首位。与乳腺癌不同,卵巢癌早期缺乏明显症状和有效筛查,生存率低。目前,美国食品药品管理局(FDA)只批准了少数卵巢癌的肿瘤标志物检测项目。卵巢癌的肿瘤标志物在疾病诊断、疗效监测和预后判断中被广泛应用。文章综述了现有卵巢癌的肿瘤标志物及其临床应用。Ovarian cancer is the fifth cause of cancer death in women, as well as the cause of deaths in gynecological cancers. Unlike breast cancer, many women die of ovarian cancer because there is no obvious symptom and no screening test in early stages. Nowadays, only a limited number of tumor markers for ovarian cancer has been cleared by U.S. Food and Drug Administration （FDA）. In general, tumor marker applications range from diagnosis and curative effect monitoring to predicting prognosis. The article will review the currently available serum markers for ovarian cancer and their clinical application.

关 键 词：糖类抗原125 人附睾蛋白4 卵巢癌 

分 类 号：R446.62[医药卫生—诊断学]